Home | Log in or Sign Up for full access | Tracked Organizations | Recent Tracked Activities

Recent Activities

Activities between Nov. 15, 2024, 8:08 p.m. and Nov. 22, 2024, 8:08 p.m. from: Stem Cell Services.

Click on a document link to see the original source document. Click on the name of an organization to see more organization linkages and timelines.


OverT Bio Receives $120K G-Rex® Grant to Propel Solid Tumor Cell Therapy Advancements

Document Date: Nov. 22, 2024, 2 p.m. / Source: Business Wire
Activity Class: CorporateFinanceActivity / Type: Investment / Region: Bio
Investor: Target: Document Extract: OverT Bio, an NYC - based cell therapy company, today announced that it has been awarded a $ 120,000 G-Rex Grant from ScaleReadyTM, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH) , and CellReadyTM.
Document Source: https://www.businesswire.com/news/home/20241122444716/en/OverT-Bio-Receives-120K-G-Rex%25C2%25AE-Grant-to-Propel-Solid-Tumor-Cell-Therapy-Advancements (archive.org page / archive.org listing)


OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development

Document Date: Nov. 20, 2024, noon / Source: GlobeNewswire
Activity Class: PartnershipActivity / Region: United Kingdom of Great Britain and Northern Ireland
Partnership: Document Extract: OXB to host a free webinar on accelerating development of viral vectors through automated manufacturing and analytical development. Oxford, UK - 20 November 2024: OXB (LSE: OXB) , a quality and innovation - led cell and gene therapy CDMO, today announces it will host a free 60-minute webinar exploring how advanced robotics can be used to speed up the development of viral vector drug products. The webinar titled "Accelerating Viral Vector Manufacturing: The Use of Automation from Early Stage to QC Release" will be held on Monday 9 December 2024 at 16:00 GMT / 11:00 EST / 17:00 CET. The webinar will feature presentations by: André Raposo, PhD, Director, Innovation Department at OXB.
Document Source: https://www.globenewswire.com/news-release/2024/11/20/2984302/0/en/OXB-to-host-a-free-webinar-on-accelerating-development-of-viral-vectors-through-automated-manufacturing-and-analytical-development.html (archive.org page / archive.org listing)


BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Document Date: Nov. 21, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: State of Israel
Partnership: Document Extract: TEL AVIV, Israel, Nov. 21, 2024 /PRNewswire/ - BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX) , a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, and Ayrmid Ltd. ("Ayrmid") , the parent company of Gamida Cell Ltd., today announced that on November 20, 2024, the companies entered into a license agreement for motixafortide (commercially sold in the U.S. as APHEXDA®) , BioLineRx's FDA-approved stem cell mobilization agent indicated in combination with filgrastim (G-CSF) for collection and subsequent autologous transplantation in patients with multiple myeloma. Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA (motixafortide) in the Asia region. In exchange for the license, BioLineRx will receive a $ 10 million upfront payment and is also eligible to receive up to an additional $ 87 million of potential commercial milestones, plus royalties ranging from 18 % to 23 % on net sales of APHEXDA. Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell's OMISIRGE®, the first and only FDA-approved, nicotinamide (NAM) -modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant.
Document Source: https://www.prnewswire.com/news-releases/biolinerx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-commercialize-aphexda-motixafortide-through-gamida-cell-ltd-302312746.html (archive.org page / archive.org listing)


BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Document Date: Nov. 21, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: United States
Partnership: Document Extract: Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA (motixafortide) in the Asia region. In exchange for the license, BioLineRx will receive a $ 10 million upfront payment and is also eligible to receive up to an additional $ 87 million of potential commercial milestones, plus royalties ranging from 18 % to 23 % on net sales of APHEXDA. Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell's OMISIRGE®, the first and only FDA-approved, nicotinamide (NAM) -modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx's U.S. - based commercial organization, who will support both stem cell transplant drugs.
Document Source: https://www.prnewswire.com/news-releases/biolinerx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-commercialize-aphexda-motixafortide-through-gamida-cell-ltd-302312746.html (archive.org page / archive.org listing)


BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Document Date: Nov. 21, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: Asia, State of Israel
Partnership: Document Extract: Under the terms of the agreement, BioLineRx granted Ayrmid an exclusive license to develop and commercialize APHEXDA (motixafortide) across all indications, excluding solid tumor indications, and in all territories other than Asia. BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA (motixafortide) in the Asia region. In exchange for the license, BioLineRx will receive a $ 10 million upfront payment and is also eligible to receive up to an additional $ 87 million of potential commercial milestones, plus royalties ranging from 18 % to 23 % on net sales of APHEXDA. Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell's OMISIRGE®, the first and only FDA-approved, nicotinamide (NAM) -modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx's U.S. - based commercial organization, who will support both stem cell transplant drugs.
Document Source: https://www.prnewswire.com/news-releases/biolinerx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-commercialize-aphexda-motixafortide-through-gamida-cell-ltd-302312746.html (archive.org page / archive.org listing)


BioLineRx and Ayrmid Ltd. Enter into Exclusive License Agreement to Commercialize APHEXDA® (motixafortide) through Gamida Cell Ltd.

Document Date: Nov. 21, 2024, 11:30 a.m. / Source: PR Newswire
Activity Class: PartnershipActivity / Region: United States
Partnership: Document Extract: BioLineRx previously granted an exclusive license agreement to Gloria Biosciences for APHEXDA (motixafortide) in the Asia region. In exchange for the license, BioLineRx will receive a $ 10 million upfront payment and is also eligible to receive up to an additional $ 87 million of potential commercial milestones, plus royalties ranging from 18 % to 23 % on net sales of APHEXDA. Ayrmid will add APHEXDA to its commercial portfolio, which also includes Gamida Cell's OMISIRGE®, the first and only FDA-approved, nicotinamide (NAM) -modified cell therapy for patients with hematologic malignancies in need of a stem cell transplant. As part of this transaction, Ayrmid expects to transition certain members of BioLineRx's U.S. - based commercial organization, who will support both stem cell transplant drugs. Through this transaction, BioLineRx will significantly reduce its long-term debt and operational expenses, which will be reviewed in detail during the company's upcoming Q3 results conference call and webcast.
Document Source: https://www.prnewswire.com/news-releases/biolinerx-and-ayrmid-ltd-enter-into-exclusive-license-agreement-to-commercialize-aphexda-motixafortide-through-gamida-cell-ltd-302312746.html (archive.org page / archive.org listing)

Archive.org page links will work if the page has already been archived by archive.org, but we can't guarantee which pages archive.org has archived so far.

Treat sameAsNameOnly relationship as same? Yes (Turn Off)

Site Stats | About (includes privacy and cookie notices)
(c) by 1145, 2023-2024. Data licensed under the Open Database License. Please send an email if you need a non-share-alike license and/or you need API access.